Ventas, Inc. (VTR)
- Previous Close
66.07 - Open
66.07 - Bid 64.62 x 900
- Ask 66.51 x 800
- Day's Range
65.39 - 66.48 - 52 Week Range
46.66 - 71.36 - Volume
2,296,848 - Avg. Volume
3,400,883 - Market Cap (intraday)
29.596B - Beta (5Y Monthly) 0.97
- PE Ratio (TTM)
198.73 - EPS (TTM)
0.33 - Earnings Date Jul 30, 2025 - Aug 4, 2025
- Forward Dividend & Yield 1.92 (2.91%)
- Ex-Dividend Date Mar 31, 2025
- 1y Target Est
76.00
Ventas, Inc. (NYSE: VTR) is a leading S&P 500 real estate investment trust enabling exceptional environments that benefit a large and growing aging population. With approximately 1,350 properties in North America and the United Kingdom, Ventas occupies an essential role in the longevity economy. The Company's growth is fueled by its over 800 senior housing communities, which provide valuable services to residents and enable them to thrive in supported environments. The Ventas portfolio also includes outpatient medical buildings, research centers and healthcare facilities. The Company aims to deliver outsized performance by leveraging its unmatched operational expertise, data-driven insights from its Ventas OI platform, extensive relationships and strong financial position. Ventas's seasoned team of talented professionals shares a commitment to excellence, integrity and a common purpose of helping people live longer, healthier, happier lives.
www.ventasreit.com498
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: VTR
View More
Performance Overview: VTR
Trailing total returns as of 5/8/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VTR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VTR
View MoreValuation Measures
Market Cap
29.60B
Enterprise Value
42.34B
Trailing P/E
198.73
Forward P/E
178.57
PEG Ratio (5yr expected)
1.79
Price/Sales (ttm)
5.50
Price/Book (mrq)
2.58
Enterprise Value/Revenue
8.33
Enterprise Value/EBITDA
21.05
Financial Highlights
Profitability and Income Statement
Profit Margin
2.81%
Return on Assets (ttm)
1.92%
Return on Equity (ttm)
1.38%
Revenue (ttm)
5.06B
Net Income Avi to Common (ttm)
142.33M
Diluted EPS (ttm)
0.33
Balance Sheet and Cash Flow
Total Cash (mrq)
182.34M
Total Debt/Equity (mrq)
108.90%
Levered Free Cash Flow (ttm)
869.68M
Research Analysis: VTR
View MoreResearch Reports: VTR
View MoreVentas Earnings: Decelerating Same-Store NOI Growth Slightly Better Than We Anticipated
Ventas owns a diversified healthcare portfolio of almost 1,400 in-place properties spread across the senior housing, medical office, hospital, life science, and skilled nursing/post-acute care. The portfolio includes almost 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to the United States. The firm also owns mortgages and other loans, contributing about 1% of net operating income.
RatingPrice TargetVentas Should See Years of Strong Growth as Senior Housing Demand Outpaces Supply
Ventas owns a diversified healthcare portfolio of almost 1,400 in-place properties spread across the senior housing, medical office, hospital, life science, and skilled nursing/post-acute care. The portfolio includes almost 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to the United States. The firm also owns mortgages and other loans, contributing about 1% of net operating income.
RatingPrice TargetVentas Should See Years of Strong Growth as Senior Housing Demand Outpaces Supply
Ventas owns a diversified healthcare portfolio of almost 1,400 in-place properties spread across the senior housing, medical office, hospital, life science, and skilled nursing/post-acute care. The portfolio includes almost 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to the United States. The firm also owns mortgages and other loans, contributing about 1% of net operating income.
RatingPrice TargetArgus Quick Note: Weekly Stock List for 03/10/2025: Trading on Volatility
Most clients of Argus Research are buy-and-hold investors. As such, our proprietary BUY-HOLD-SELL ratings and target prices are established with one-year time horizons. We also have five-year ratings for even longer-term investors. But we do have select hedge fund clients that are looking for more trading opportunities or for long/short portfolio ideas. The early weeks of 2025, with roller-coaster ups and downs in stock prices, likely have provided more opportunities for momentum traders than for fundamental investors. Indeed, the VIX Volatility Index is near 24, up from 17 at the start of the year and above the historical average of 20. The list below includes some of the shorter-term trading ideas our analysts and strategists have identified recently. All stocks are rated BUY at Argus.